ArticleSmall science2024
A Tumor Targeting Strategy of Phytoflavonoid Biochanin A for Efficient Fluorescence-Guided Chemotherapy.
Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer chemotherapy using natural phytochemicals, especially including isoflavone biochanin A (BCA), has attracted considerable attention because of the potent antitumor therapeutic effect and excellent biosafety. However, the preclinical application of BCA is still generally limited by its poor water solubility and low biological availability. To overcome these important limitations, a tumor targetable hemicyanine-based near-infrared (NIR) theranostic agent is rationally designed and prepared to improve the water solubility, tumor targetability, and antitumor activity of BCA. A key point to enhance the tumor targeting efficiency of BCA is the combination of a tumor-targeted water-soluble zwitterionic NIR fluorophore (ZW800-Cl) and BCA to create the hemicyanine structure, named BCA-ZW. Owing to the long-wavelength emission (>750 nm) and large Stokes shift (72 nm) of BCA-ZW, the in vivo performance of BCA-ZW is effectively monitored. The molecularly engineered BCA-ZW not only exhibits high targeting ability to HT-29 xenograft tumors but also induces high levels of reactive oxygen species (ROS) generation in the tumor tissues. Therefore, the fluorescence-guided chemotherapy by BCA-ZW to the tumor-bearing mouse model achieves the enhanced antitumor effect of BCA. This work provides a simple but effective strategy to design NIR fluorescent phytoflavonoids as potential therapeutic agents for further biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.